Tectonic Therapeutic (TECX) Preferred Stock Liabilities (2017 - 2025)
Tectonic Therapeutic (TECX) reported Preferred Stock Liabilities of $0.1 for Q4 2025, down 100.0% quarter-over-quarter from $80.6 million in Q4 2023.
Tectonic Therapeutic (TECX) Preferred Stock Liabilities (2017 - 2025) Analysis & Trends
Tectonic Therapeutic (TECX) has 3 years of Preferred Stock Liabilities data on file, last reported at $0.1 in Q4 2025.
- Preferred Stock Liabilities for Q4 2025 came in at $0.1, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $0.1 (changed N/A YoY), and the FY2025 annual result was $0.1, changed N/A from the prior year.
- Preferred Stock Liabilities declined to $0.1 in Q4 2025 per TECX's latest filing, from $80.6 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $80.6 million in Q4 2023 and troughed at $0.1 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Tectonic Therapeutic | 528.16 Mn | 291.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.10 |
| Dec 31, 2023 | 80.63 Mn |
| Dec 31, 2017 | 26.50 Mn |